4D Molecular Therapeutics Inc

FDMT

8.570USD

-0.760-8.15%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

4D Molecular Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

39 / 391

Overall Ranking

140 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

4D Molecular Therapeutics Inc Highlights

StrengthsRisks

4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 311.18% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 85.21M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 85.21M.

Fairly Valued

The company’s latest PE is -3.54, at a medium 3-year percentile range.

Held by HOTCHKIS & WILEY

Star Investor HOTCHKIS & WILEY holds 2.57K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.89.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

31.333

Target Price

+235.83%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of 4D Molecular Therapeutics Inc is 7.15, ranking 121 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 85.09M, representing a year-over-year increase of 8508900.00%, while its net profit experienced a year-over-year increase of 139.05%.

Score

Industry at a Glance

Previous score

7.15

Change

0



Financials

7.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.90

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.14

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of 4D Molecular Therapeutics Inc is 7.76, ranking 79 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.54, which is -77.76% below the recent high of -0.79 and -292.83% above the recent low of -13.92.

Score

Industry at a Glance

Previous score

7.76

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 39/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of 4D Molecular Therapeutics Inc is 8.18, ranking 155 out of 391 in the Biotechnology & Medical Research industry. The average price target is 33.00, with a high of 45.00 and a low of 17.00.

Score

Industry at a Glance

Previous score

8.18

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of 4D Molecular Therapeutics Inc is 6.68, ranking 147 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 10.20 and the support level at 7.45, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.22

Change

-0.54

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-30

The current institutional shareholding score of 4D Molecular Therapeutics Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 123.08%, representing a quarter-over-quarter decrease of 0.59%. The largest institutional shareholder is The Vanguard, holding a total of 3.09M shares, representing 6.06% of shares outstanding, with 1.80% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

4.56M

--

Janus Henderson Investors

1.75M

-0.06%

BVF Partners L.P.

4.63M

--

Goldman Sachs & Company, Inc.

3.71M

-0.86%

Novo Holdings A/S

3.17M

+58.75%

BlackRock Institutional Trust Company, N.A.

3.01M

-3.49%

The Vanguard Group, Inc.

Star Investors

2.58M

-5.90%

State Street Investment Management (US)

903.77K

-6.05%

Armistice Capital LLC

1.10M

+265.33%

Kirn (David)

1.66M

-0.02%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of 4D Molecular Therapeutics Inc is 3.42, ranking 141 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 2.86. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

4D Molecular Therapeutics Inc

FDMT

7.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.55 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.50 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.24 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.23 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.16 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment